Company profile: GlobeImmune
1.1 - Company Overview
Company description
- Provider of a proprietary Tarmogenยฎ platform used to develop products for the treatment of cancer and infectious diseases.
Products and services
- Cancer Treatment Products: Engineers platform-based therapeutics using the Tarmogenยฎ technology to construct products specifically intended for the treatment of cancer
- Infectious Disease Treatment Products: Architects platform-based therapeutics using the Tarmogenยฎ technology to build products specifically intended for the treatment of infectious diseases
- Tarmogenยฎ Platform: Proprietary technology platform used to develop products for the treatment of cancer and infectious diseases
Key contacts
๐
๐
Financial details
๐
1.2 - Competitors and similar companies to GlobeImmune
Xenikos
HQ: The Netherlands
Website
- Description: Provider of antibody-based immunotherapies, developing a combination of two toxin-loaded anti-T-cell antibodies to quickly reset the immune system in patients with serious immune diseases or transplant rejection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: โโโโโ
- Total funding raised: $โโโm
- Backers: โโโโโโโโโโ
- Acquisitions: โโ
View full Xenikos company profile โ
Enumeral Biomedical
HQ: United States
Website
- Description: Provider of a nanotechnology-enabled process for therapeutic discovery, immune profiling, and personalized medicine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: โโโโโ
- Total funding raised: $โโโm
- Backers: โโโโโโโโโโ
- Acquisitions: โโ
View full Enumeral Biomedical company profile โ
Theravectys
HQ: France
Website
- Description: Provider of a proprietary lentiviral vector platform for developing vaccines and immunotherapies to prevent and treat infectious diseases, cancers, and other conditions. Pipeline includes Lenti-HPV-07 (Phase 1) for HPV16/18-induced oropharyngeal and cervical cancers, Lenti-COVID intranasal vaccine for SARS-CoV-2 variants, and LV-DEN tetravalent T-cell dengue vaccine. Initial clinical focus includes HIV/AIDS.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: โโโโโ
- Total funding raised: $โโโm
- Backers: โโโโโโโโโโ
- Acquisitions: โโ
View full Theravectys company profile โ
Apthera
HQ: United States
Website
- Description: Provider of peptide-based cancer immunotherapy solutions for the treatment of breast and prostate cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: โโโโโ
- Total funding raised: $โโโm
- Backers: โโโโโโโโโโ
- Acquisitions: โโ
View full Apthera company profile โ
Scancell
HQ: United Kingdom
Website
- Description: Provider of immunotherapy platforms and therapeutic vaccines for cancer and infectious diseases, including ImmunoBody and Moditope for cancer vaccines, GlyMab for glycan-targeting monoclonal antibodies, AvidiMab to enhance antibody potency and tumor specificity, and melanoma vaccines SCIB1 and iSCIB1+.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: โโโโโ
- Total funding raised: $โโโm
- Backers: โโโโโโโโโโ
- Acquisitions: โโ
View full Scancell company profile โ
๐
2.M&A buyers
2.1 Potential strategic acquirers in the sector
๐
๐
๐
๐
View all strategic buyers with complete profiles
Start Free Trial โ
2.2 - Strategic buyer groups for GlobeImmune
๐
Buyer group 1: โโโโโโโโ โโโโโโโโ
โโ companies
Description: โโโโโโโโ โโโโโโโโ โโโโโโโโ โโโโโโโโ โโโโโโโโ โโโโโโโโ โโโโโโโโ โโโโโโโโ โโโโโโโโ โโโโโโโโ
Key Products: โโโโโโโโ, โโโโโโโโ, โโโโโโโโ, โโโโโโโโ
๐
View all companies in this group
Request Free Trial Now โ
๐
Buyer group 2: โโโโโโโโ โโโโโโโโ
โโ companies
Description: โโโโโโโโ โโโโโโโโ โโโโโโโโ โโโโโโโโ โโโโโโโโ โโโโโโโโ โโโโโโโโ โโโโโโโโ โโโโโโโโ โโโโโโโโ
Key Products: โโโโโโโโ, โโโโโโโโ, โโโโโโโโ, โโโโโโโโ
๐
View all companies in this group
Request Free Trial Now โ
๐
Buyer group 3: โโโโโโโโ โโโโโโโโ
โโ companies
Description: โโโโโโโโ โโโโโโโโ โโโโโโโโ โโโโโโโโ โโโโโโโโ โโโโโโโโ โโโโโโโโ โโโโโโโโ โโโโโโโโ โโโโโโโโ
Key Products: โโโโโโโโ, โโโโโโโโ, โโโโโโโโ, โโโโโโโโ
๐
View all companies in this group
Request Free Trial Now โ
๐ Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial โ
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to GlobeImmune
2.2 - Growth funds investing in similar companies to GlobeImmune
๐
View all growth equity funds with complete profiles
Start Free Trial โ
4 - Top valuation comps for GlobeImmune
4.2 - Public trading comparable groups for GlobeImmune
๐ Unlock all public trading comparable groups with complete valuation data
Start Free Trial โ